The Rapidly Emerging Antiviral Drug Development Initiative (READDI) is working to give humanity an early advantage against future diseases.

Facing the next challenge now.

It can feel impossible to look beyond the ongoing COVID-19 crisis. But the emergence of another deadly virus is a matter of when, not if. That means instead of remaining reactive, we must begin preparing today for the outbreaks ahead.
​
Learn More

Focusing on antiviral solutions.

Our goal is five broad-spectrum antiviral drugs in five years, requiring a radical rethinking of the drug discovery and development process, so they can be rapidly deployed against new viruses as they materialize. 
​
See How

Sharing science at an unprecedented scale.

Through our global access model we can harness the power and knowledge of our partners to deliver novel therapeutics ready to combat the next pandemic. 
​
​
​
Meet Our Partners

How you can support the mission of READDI.

COVID-19 has made it painfully clear: humanity cannot afford to be caught unprepared by another pandemic. These deadly viruses are bigger than any one company, government or institution. Stopping them requires a unified global collaboration across disciplines, working toward the common goal of a safer future. That is what READDI aims to achieve.

We are actively seeking partnerships to advance our scientific mission, as well as philanthropic, private sector and government resources. 

Get Involved

---

Aled Edwards, Director, Structural Genomics Consortium (SGC)

"The purpose of READDI is to harness all the smart people toward the specific objective of making medicines to prevent the next pandemic."

---

What we do today could make all the difference.

As we work to mitigate the risk of future pandemics, science will lead our efforts, innovation will accelerate them and global partnerships will scale the best of what we create together.

News

The University of North Carolina-Chapel Hill, Eshelman Institute for Innovation and Structural Genomics Consortium announce historic READDI partnership. 

See More News